CompletedNot Applicable

Research Study in Healthy Volunteers of Patients With Fanconi Anemia, Myeloproliferative Disorders, or Myeloma

United States213 participantsStarted 1975-06

Plain-language summary

RATIONALE: Analyzing tissue and blood samples from healthy volunteers or patients with Fanconi anemia, myelodysplasia, myeloproliferative disorders, or myeloma in the laboratory may help doctors learn more about the causes of blood cancers. PURPOSE: The purpose of this study is to analyze in the laboratory blood and bone marrow cells from healthy volunteers or patients with Fanconi anemia, myeloproliferative disorders, or myeloma.

Who can participate

Age range

1 Year – 55 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

DISEASE CHARACTERISTICS: * Meets 1 of the following criteria: * Diagnosis of one of the following: * Fanconi's anemia requiring bone marrow biopsy as part of standard care (adults and children) * Myeloproliferative disorder or myeloma (adults) * Healthy volunteer, meeting 1 of the following criteria: * Over 18 years of age * Bone marrow transplant donor (children) PATIENT CHARACTERISTICS: * Hemoglobin \> 13 g/dL * White blood cells (WBC) \> 4,000/mm³ * Platelet count \> 150,000/mm³ * No clinical signs or symptoms of acute or subacute infections (viral, bacterial, or fungal) * No known blood abnormality (healthy volunteers) * No allergies to lidocaine or xylocaine PRIOR CONCURRENT THERAPY: * Not specified

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Loss of function analyses

Timeframe: Duration of the study

Proteins binding to Fanconi anemia, complementation group C (FACC) gene-product by affinity chromatography of nuclear and whole cell lysates of normal cells

Timeframe: Duration of the study

Screening of proteins binding to FACC gene-product using monoclonal antibodies specific to signal transduction and cell cycle proteins

Timeframe: Duration of the study

Microsequencing of unique proteins

Timeframe: Duration of the study

Location of specific downstream block point imposed by antisense molecules using antibodies specific to signal transduction, cell cycle, or repair proteins for the FACC protein

Timeframe: Duration of the study

Affirmation that the block points identified are recapitulated in progenitor cells from peripheral blood

Timeframe: Duration of the study

Trial details

NCT IDNCT00900055

SponsorOHSU Knight Cancer Institute

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2016-08-23

View on ClinicalTrials.gov More Chronic Myeloproliferative Disorders trials

Plain-language summary

Who can participate

Age range

1 Year – 55 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

What they're measuring

Loss of function analyses

Timeframe: Duration of the study

Proteins binding to Fanconi anemia, complementation group C (FACC) gene-product by affinity chromatography of nuclear and whole cell lysates of normal cells

Timeframe: Duration of the study

Screening of proteins binding to FACC gene-product using monoclonal antibodies specific to signal transduction and cell cycle proteins

Timeframe: Duration of the study

Microsequencing of unique proteins

Timeframe: Duration of the study

Location of specific downstream block point imposed by antisense molecules using antibodies specific to signal transduction, cell cycle, or repair proteins for the FACC protein

Timeframe: Duration of the study

Affirmation that the block points identified are recapitulated in progenitor cells from peripheral blood

Timeframe: Duration of the study